NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China [Yahoo! Finance]
NewcelX Ltd. - Ordinary Shares (NCEL)
Company Research
Source: Yahoo! Finance
ZURICH Dec. 11, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today announced the publication of a major international patent application in China covering a new class of quinazoline, benzothiazine, and benzoxazine derivatives (DOXA) for the treatment of neurological diseases. This publication marks an important expansion of the Company's proprietary small-molecule portfolio, supporting NewcelX's strategy of advancing therapeutic innovation across sleep-wake disorders, neurodegeneration, and metabolic disease. This represents a meaningful expansion of NewcelX's proprietary small-molecule technology estate as the Company advances its innovation strategy across cell therapy, regenerative medicine, and CNS drug development. Key Patent Information Priority: Europe Patent Application No. 22307075.6, filed December 30, 2022 PCT Filing: International Patent Application
Show less
Read more
Impact Snapshot
Event Time:
NCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NCEL alerts
High impacting NewcelX Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NCEL
News
- NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in ChinaPR Newswire
- NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological InstitutePR Newswire
- NLS Pharmaceutics (NASDAQ:NCEL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NCEL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory BoardPR Newswire
- NewcelX CEO Issues Letter to ShareholdersPR Newswire
NCEL
Sec Filings
- 12/11/25 - Form 6-K
- 11/20/25 - Form 6-K
- NCEL's page on the SEC website